BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis

Company Overview

BioMarin Pharmaceutical (NASDAQ:BMRN) is a global biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare genetic and metabolic diseases. Founded in 1997 and headquartered in San Rafael, California, BioMarin focuses on enzyme replacement therapies, small molecule treatments and gene therapies. Its portfolio includes approved products such as Naglazyme for mucopolysaccharidosis VI, Kuvan for phenylketonuria, Vimizim for mucopolysaccharidosis IVA, and Brineura for CLN2 disease. The company’s research pipeline emphasizes both next-generation enzyme replacements and transformative gene therapy candidates aimed at conditions with high unmet medical need.

BioMarin’s operations span North America, Europe, Latin America and the Asia-Pacific region, with manufacturing facilities in the United States and Switzerland. The company collaborates with academic institutions, patient advocacy groups and strategic partners to advance clinical development and expand global access to its therapies. BioMarin leverages state-of-the-art manufacturing technologies for enzyme purification and viral vector production, supporting both commercial supply and a robust gene therapy research program. Its commitment to patient support extends beyond treatment delivery, encompassing educational resources and financial assistance initiatives for rare disease communities.

Under the leadership of President and Chief Executive Officer Jean-Jacques Bienaimé, BioMarin has built a strong track record of research productivity and regulatory achievement. The management team blends expertise in biotechnology, regulatory affairs and global commercialization to navigate the complexities of rare disease drug development. As the company advances late-stage trials in areas such as hemophilia A gene therapy, phenylketonuria gene therapy and other rare disorders, BioMarin remains focused on delivering durable clinical benefits and expanding its reach to underserved patient populations worldwide.

Key Stats

• Today's Range: $56.52 to $58.67
• 50-Day Range: $54.08 to $61.37
• 52-Week Range: $52.93 to $94.85
• Volume: 1.27 million shs
• Average Volume: 1.74 million shs
• Market Capitalization: $10.86 billion
• P/E Ratio: 21.05
• Dividend Yield: N/A
• Price Target: $93.78
• Consensus Rating: Moderate Buy

BioMarin Pharmaceutical Stock Analysis - MarketRank™

BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 10th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 18 buy ratings, 6 hold ratings, and no sell ratings.

Amount of Analyst Coverage

BioMarin Pharmaceutical has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 38.41%

Earnings Growth

Earnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioMarin Pharmaceutical is 21.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioMarin Pharmaceutical is 21.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.58.

Price to Earnings Growth Ratio

BioMarin Pharmaceutical has a PEG Ratio of 0.79. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

BioMarin Pharmaceutical has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of BioMarin Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioMarin Pharmaceutical has recently increased by 47.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioMarin Pharmaceutical does not currently pay a dividend.

Dividend Growth

BioMarin Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -2.93

Percentage of Shares Shorted

3.43% of the float of BioMarin Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

BioMarin Pharmaceutical has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioMarin Pharmaceutical has recently increased by 47.51%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.19

News Sentiment

BioMarin Pharmaceutical has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for BioMarin Pharmaceutical this week, compared to 12 articles on an average week.

Search Interest

17 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.

MarketBeat Follows

6 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,651.00 in company stock.

Percentage Held by Insiders

Only 0.85% of the stock of BioMarin Pharmaceutical is held by insiders.

Percentage Held by Institutions

98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMRN Stock Analysis - Frequently Asked Questions

How have BMRN shares performed this year?

BioMarin Pharmaceutical's stock was trading at $65.73 at the start of the year. Since then, BMRN shares have decreased by 13.9% and is now trading at $56.62.

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The biotechnology company earned $747.31 million during the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 11.34% and a net margin of 17.76%.
Read the conference call transcript.

Who are BioMarin Pharmaceutical's major shareholders?

Top institutional shareholders of BioMarin Pharmaceutical include Assenagon Asset Management S.A. (0.54%), Swedbank AB (0.23%), Covea Finance (0.07%) and Wealth Enhancement Advisory Services LLC (0.04%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, Cristin Hubbard, V Bryan Lawlis, Erin Burkhart and Mark J Alles.
View institutional ownership trends.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BMRN
• CIK: 1048477
• Web: www.bmrn.com
• Phone: (415) 506-6700
• Fax: 415-382-7889
• Employees: 3,040
• Year Founded: 1997

Price Target and Rating

• Average Price Target for BioMarin Pharmaceutical: $93.78
• High Price Target: $126.00
• Low Price Target: $65.00
• Potential Upside/Downside: +65.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.69
• Trailing P/E Ratio: 21.05
• Forward P/E Ratio: 17.97
• P/E Growth: 0.79
• Net Income: $426.86 million
• Net Margins: 17.76%
• Pretax Margin: 22.86%
• Return on Equity: 11.34%
• Return on Assets: 8.95%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 5.52
• Quick Ratio: 3.49

Sales & Book Value

• Annual Sales: $2.85 billion
• Price / Sales: 3.80
• Cash Flow: $3.16 per share
• Price / Cash Flow: 17.94
• Book Value: $29.69 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 191,780,000
• Free Float: 190,146,000
• Market Cap: $10.86 billion
• Optionable: Optionable
• Beta: 0.17